Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Baues

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Frontiers in Pharmacology|June 4, 2019
Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint InhibitionMaike Trommer, Sin Yuin Yeo, Thorsten Persigehl, et al.
Frontiers in Oncology|June 11, 2021
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-PatientsJohannes Rosenbrock, Andrés Vásquez-Torres, Horst Mueller, et al.
Leukemia & Lymphoma|June 25, 2019
Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphomaChristian Baues, Helen Görgen, Robert Semrau, et al.
Frontiers in Oncology|May 22, 2023
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trialMichael Oertel, Dominik Hering, Christian Baues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose ChemotherapyPaul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Frontiers in Pharmacology|February 22, 2020
Corrigendum: Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint InhibitionMaike Trommer, Sin Yuin Yeo, Thorsten Persigehl, et al.
Radiation Oncology (London, England)|January 3, 2025
Optimising (re-)irradiation for locally recurrent head and neck cancer: impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes-a single centre analysisJulia Katharina Schleifenbaum, Janis Morgenthaler, Shachi Jenny Sharma, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
The Lancet. Haematology|October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trialsBastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 13, 2021
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approachPhilipp Linde, Christian Baues, Simone Wegen, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Frontiers in Pharmacology|June 4, 2019
Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint InhibitionMaike Trommer, Sin Yuin Yeo, Thorsten Persigehl, et al.
Frontiers in Oncology|June 11, 2021
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-PatientsJohannes Rosenbrock, Andrés Vásquez-Torres, Horst Mueller, et al.
Leukemia & Lymphoma|June 25, 2019
Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphomaChristian Baues, Helen Görgen, Robert Semrau, et al.
Frontiers in Oncology|May 22, 2023
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trialMichael Oertel, Dominik Hering, Christian Baues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose ChemotherapyPaul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Frontiers in Pharmacology|February 22, 2020
Corrigendum: Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint InhibitionMaike Trommer, Sin Yuin Yeo, Thorsten Persigehl, et al.
Radiation Oncology (London, England)|January 3, 2025
Optimising (re-)irradiation for locally recurrent head and neck cancer: impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes-a single centre analysisJulia Katharina Schleifenbaum, Janis Morgenthaler, Shachi Jenny Sharma, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
The Lancet. Haematology|October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trialsBastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|February 13, 2021
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approachPhilipp Linde, Christian Baues, Simone Wegen, et al.
Pageof 9